SPTBN2 regulates endometroid ovarian cancer cell proliferation, invasion and migration via ITGB4‑mediated focal adhesion and ECM receptor signalling pathway

Yang,La; Gu,Yuanyuan

doi:10.3892/etm.2023.11977

SPTBN2 regulates endometroid ovarian cancer cell proliferation, invasion and migration via ITGB4‑mediated focal adhesion and ECM receptor signalling pathway

Authors:
- La Yang
- Yuanyuan Gu
View Affiliations

Affiliations: Department of Obstetrics and Gynaecology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550001, P.R. China
Published online on: April 24, 2023 https://doi.org/10.3892/etm.2023.11977
Article Number: 277
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is as a major contributor to gynaecologic death globally. The present study aimed to investigate the regulatory role of spectrin β non‑erythrocytic 2 gene (SPTBN2) in endometroid ovarian cancer and its mechanism of action. According to the Gene Expression Profiling Interactive Analysis (GEPIA) database, SPTBN2 expression is elevated in ovarian cancer tissues and higher SPTBN2 expression indicated a worse prognosis. The present study assessed SPTBN2 mRNA and protein expression levels by reverse transcription‑quantitative PCR and western blotting, respectively. Cell viability, proliferation, migration and invasion were assessed with Cell Counting Kit‑8, 5‑ethynyl‑2'‑deoxyuridine incorporation, wound healing and Transwell assays, respectively. SPTBN2 expression was notably enhanced in ovarian cancer cell lines, especially in A2780 cells compared with HOSEPiC cells (P<0.001). Following transfection with small interfering (si)RNA targeting SPTBN2, the viability, proliferation, migration and invasion of A2780 cells were decreased compared with those of A2780 cells transfected with siRNA‑NC (P<0.001). Gene Set Enrichment Analysis database revealed that SPTBN2 was primarily enriched in ‘focal adhesion’ and ‘extracellular matrix (ECM)‑receptor interaction’, whereas SPTBN2 was significantly associated with integrin β4 (ITGB4) in the GEPIA database. In addition, rescue experiments were performed to determine the mechanism of SPTBN2 in endometroid ovarian cancer. ITGB4 overexpression reversed the inhibitory effects of the SPTBN2 knockdown on viability, proliferation, migration and invasion of A2780 cells (P<0.05). The impacts of SPTBN2 on the expression of focal adhesion and downstream ECM receptor signalling‑related proteins, including Src and p‑FAK/FAK, were significantly reversed by ITGB4 overexpression (P<0.01). Collectively, SPTBN2 may regulate endometroid ovarian cancer cell proliferation, invasion and migration through the ITGB4‑mediated focal adhesion and ECM receptor signalling pathway.

View Figures

View References

1	Torre LA, Islami F, Siegel RL, Ward EM and Jemal A: Global cancer in women: Burden and trends. Cancer Epidemiol Biomarkers Prev. 26:444–457. 2017.PubMed/NCBI View Article : Google Scholar
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020.PubMed/NCBI View Article : Google Scholar
3	Rooth C: Ovarian cancer: Risk factors, treatment and management. Br J Nurs. 22:S23–S30. 2013.PubMed/NCBI View Article : Google Scholar
4	Jelovac D and Armstrong DK: Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 61:183–203. 2011.PubMed/NCBI View Article : Google Scholar
5	Moufarrij S, Dandapani M, Arthofer E, Gomez S, Srivastava A, Lopez-Acevedo M, Villagra A and Chiappinelli KB: Epigenetic therapy for ovarian cancer: Promise and progress. Clin Epigenetics. 11(7)2019.PubMed/NCBI View Article : Google Scholar
6	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI View Article : Google Scholar
7	Kim SI and Kim JW: Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer. ESMO Open. 6(100149)2021.PubMed/NCBI View Article : Google Scholar
8	Liu HD, Xia BR, Jin MZ and Lou G: Organoid of ovarian cancer: Genomic analysis and drug screening. Clin Transl Oncol. 22:1240–1251. 2020.PubMed/NCBI View Article : Google Scholar
9	Jackson M, Song W, Liu MY, Jin L, Dykes-Hoberg M, Lin CI, Bowers WJ, Federoff HJ, Sternweis PC and Rothstein JD: Modulation of the neuronal glutamate transporter EAAT4 by two interacting proteins. Nature. 410:89–93. 2001.PubMed/NCBI View Article : Google Scholar
10	Bian X, Wang S, Jin S, Xu S, Zhang H, Wang D, Shang W and Wang P: Two novel missense variants in SPTBN2 likely associated with spinocerebellar ataxia type 5. Neurol Sci. 42:5195–5203. 2021.PubMed/NCBI View Article : Google Scholar
11	Wu C, Dong B, Huang L, Liu Y, Ye G, Li S and Qi Y: SPTBN2, a new biomarker of lung adenocarcinoma. Front Oncol. 11(754290)2021.PubMed/NCBI View Article : Google Scholar
12	Wang P, Liu T, Zhao Z, Wang Z, Liu S and Yang X: SPTBN2 regulated by miR-424-5p promotes endometrial cancer progression via CLDN4/PI3K/AKT axis. Cell Death Discov. 7(382)2021.PubMed/NCBI View Article : Google Scholar
13	Yue M, Liu T, Yan G, Luo X and Wang L: LINC01605, regulated by the EP300-SMYD2 complex, potentiates the binding between METTL3 and SPTBN2 in colorectal cancer. Cancer Cell Int. 21(504)2021.PubMed/NCBI View Article : Google Scholar
14	Forman OP, De Risio L, Stewart J, Mellersh CS and Beltran E: Genome-wide mRNA sequencing of a single canine cerebellar cortical degeneration case leads to the identification of a disease associated SPTBN2 mutation. BMC Genet. 13(55)2012.PubMed/NCBI View Article : Google Scholar
15	Han L, Wang L, Tang S, Yuan L, Wu S, Du X, Xiang Y, Qu X, Liu H, Luo H, et al: ITGB4 deficiency in bronchial epithelial cells directs airway inflammation and bipolar disorder-related behavior. J Neuroinflammation. 15(246)2018.PubMed/NCBI View Article : Google Scholar
16	Jiang X, Wang J, Wang M, Xuan M, Han S, Li C, Li M, Sun XF, Yu W and Zhao Z: ITGB4 as a novel serum diagnosis biomarker and potential therapeutic target for colorectal cancer. Cancer Med. 10:6823–6834. 2021.PubMed/NCBI View Article : Google Scholar
17	Hong D, Zhang X, Li R, Yu J, Lou Y, He Q, Li X, Xu D, Lv P, Lin J and Chen Y: Deletion of TMEM268 inhibits growth of gastric cancer cells by downregulating the ITGB4 signaling pathway. Cell Death Differ. 26:1453–1466. 2019.PubMed/NCBI View Article : Google Scholar
18	Skubitz AP, Bast RC Jr, Wayner EA, Letourneau PC and Wilke MS: Expression of alpha 6 and beta 4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. Am J Pathol. 148:1445–1461. 1996.PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
20	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017.PubMed/NCBI View Article : Google Scholar
21	Vasaikar SV, Straub P, Wang J and Zhang B: LinkedOmics: Analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 46:D956–D963. 2018.PubMed/NCBI View Article : Google Scholar
22	Kanehisa M, Sato Y, Kawashima M, Furumichi M and Tanabe M: KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44:D457–D462. 2016.PubMed/NCBI View Article : Google Scholar
23	Ferreira JA: The Benjamini-Hochberg method in the case of discrete test statistics. Int J Biostat. 3(Article 11)2007.PubMed/NCBI View Article : Google Scholar
24	Zhu T, Chen R, Wang J, Yue H, Lu X and Li J: The prognostic value of ITGA and ITGB superfamily members in patients with high grade serous ovarian cancer. Cancer Cell Int. 20(257)2020.PubMed/NCBI View Article : Google Scholar
25	Gong G, Lin T and Yuan Y: Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer. J Ovarian Res. 13(30)2020.PubMed/NCBI View Article : Google Scholar
26	Yang Z, Yu G, Guo M, Yu J, Zhang X and Wang J: CDPath: Cooperative driver pathways discovery using integer linear programming and markov clustering. IEEE/ACM Trans Comput Biol Bioinform. 18:1384–1395. 2021.PubMed/NCBI View Article : Google Scholar
27	Huang M, Long Y, Jin Y, Ya W, Meng D, Qin T, Su L, Zhou W, Wu J, Huang C and Huang Q: Comprehensive analysis of the lncRNA-miRNA-mRNA regulatory network for bladder cancer. Transl Androl Urol. 10:1286–1301. 2021.PubMed/NCBI View Article : Google Scholar
28	Zhang Z, Wang Q, Zhang M, Zhang W, Zhao L, Yang C, Wang B, Jiang K, Ye Y, Shen Z and Wang S: Comprehensive analysis of the transcriptome-wide m6A methylome in colorectal cancer by MeRIP sequencing. Epigenetics. 16:425–435. 2021.PubMed/NCBI View Article : Google Scholar
29	Feng P, Ge Z, Guo Z, Lin L and Yu Q: A comprehensive analysis of the downregulation of miRNA-1827 and its prognostic significance by targeting SPTBN2 and BCL2L1 in ovarian cancer. Front Mol Biosci. 8(687576)2021.PubMed/NCBI View Article : Google Scholar
30	Zhao SY, Wang Z, Wu XB, Zhang S, Chen Q, Wang DD and Tan QF: CERS6-AS1 contributes to the malignant phenotypes of colorectal cancer cells by interacting with miR-15b-5p to regulate SPTBN2. Kaohsiung J Med Sci. 38:403–414. 2022.PubMed/NCBI View Article : Google Scholar
31	Meng X, Liu P, Wu Y, Liu X, Huang Y, Yu B, Han J, Jin H and Tan X: Integrin beta 4 (ITGB4) and its tyrosine-1510 phosphorylation promote pancreatic tumorigenesis and regulate the MEK1-ERK1/2 signaling pathway. Bosn J Basic Med Sci. 20:106–116. 2020.PubMed/NCBI View Article : Google Scholar